Background-Alterations in the p53 gene are often found in pancreatic cancer, and accumulation of the p53 protein has been noted in tumour celils. Aims-To investigate whether serum p53 protein concentrations could be used as markers for p53 gene mutations in neoplasms of the pancreas.
(0.02) ng/ml). Adopting an arbitrary cut off value for the serum p53 protein concentration of 0-37 ng/ml, which corresponded to a value 2 SD above the mean value from the healthy blood donors, positive serum p53 protein concentrations were found in 23 out of 104 (22.1%) patients with adenocarcinomas examined, 16 out of 47 (34.0%) patients with carcinomas with distant metastases, but only seven of 57 patients (12-3%) with carcinomas without metastases (p<0.05). In 11 patients with pancreatic adenocarcinomas, the mean serum p53 protein concentration after tumour resection was 0-21 (0.05) ng/ml, and had decreased compared with the preoperative concentrations (0.05) ng/ml) (p<0.05). There were no significant associations between the serum concentrations of p53 protein and serum concentrations ofmarkers such as CA19-9 or CEA; however, serum The p53 gene is a tumour suppressor gene located on the short arm of chromosome 17. It encodes a 53 kDa nuclear phosphoprotein (p53 protein) which is thought to inhibit cellular proliferation and transformation.' Mutations of the p53 gene are the most common genetic alterations found in human malignancies.2 Most mutations of the p53 gene lead to an accumulation of p53 protein due to an increased half life. As a result, the accumulation of p53 protein reaches concentrations detectable by immunohistochemistry. By contrast, the product of the wild type p53 gene is undetectable because of its short half life.3 Thus there seems to be a good correlation between the overexpression of p53 protein and p53 gene mutations. 4 The Briefly, microtitre wells were precoated with PAb 240, a mouse monoclonal antibody specific for most native mammalian mutant p53 proteins.'9 A 100 ,u aliquot of the serum was added to each well, and was incubated at 4°C overnight. After washing the wells, 100 pLI rabbit polyclonal reporter antibody, which also recognises mutant mammalian p53 proteins, was added to each well and was incubated at room temperature for two hours. After washing the wells, 100 pLI horseradish peroxidase conjugated goat antirabbit IgG was added to each well, and was incubated at room temperature for one hour. After washing the wells again, the colourless solution was converted into a blue/ green solution by incubating each well with 100 pI chromogenic substrate 2,2'-azino-di-[3-ethyl-benzthiazoline sulphonate] at room temperature for 30 minutes. The coloured reaction product was quantified by examining its absorbance at 405 nm using a spectrophotometer. The concentration of mutant p53 protein in the serum samples was then determined by comparison against a standard curve generated from a known amount of mutant p53 protein (0, 0-25, 0 5, 1, 2, and 4 ng/ml). The minimum concentration detectable was 0-05 ng/ml according to the manufacturer. In all 104 cases with pancreatic cancer, both CA19-9 and CEA serum concentrations were also analysed by conventional methods.
IMMUNOHISTOCHEMISTRY
Matched samples for immunostaining were available in 61 cases of adenocarcinoma, six cases of benign tumours, six cases of islet cell tumours, and in four cases of chronic pancreatitis. The 61 adenocarcinoma sections consisted of 43 primary tumours and 18 metastatic tumours. They were fixed in 1 0% (v/v) formalin, and then paraffin wax embedded sections were cut at 4 pm thickness.
A mouse monoclonal antibody (mAb) against the p53 protein, DO-7, was used in this study. As DO-7 recognises the amino terminus of the p53 protein, it can react with any variant form of p53 so long as it is translated.20 In our previous study" using Table II and Fig 1 list the serum p53 protein concentrations assayed by ELISA. In adenocarcinomas of the pancreas, the serum concentrations of p53 protein ranged from 0-062 to 1-29 ng/ml, and averaged 0X27 (SEM) 0-02 ng/ ml. These concentrations were significantly higher than those in healthy blood donors (0-15 (0.02) ng/ml) (SD=0 11, p<0 005), and were also higher than in patients with chronic pancreatitis (0-15 (0-02) ng/ml) (p<005). Serum p53 concentrations in patients with chronic pancreatitis, benign tumours (0 16 (0 03) ng/ml), and islet cell tumours (0-18 (0 05) ng/ml) did not differ significantly from those of healthy blood donors. Thus patients with benign tumours, chronic pancreatitis, and healthy volunteers could be defined collectively as the non-malignant group. Serum p53 protein concentrations in the adenocarcinoma group were significantly higher than in the non-malignant group (0 15 (0-01) ng/ml) (p<0001) (data not shown).
The cut off value for the serum p53 protein concentration in the pancreatic cancer cases was arbitrarily defined as 0 37 ng/ml, which was 2 SD above the mean of the healthy blood donors. Therefore, serum p53 protein concentrations above 0-37 were defined as positive, and those below 0 37 were designated as negative. Positive serum p53 protein samples were found most often in cases of pancreatic carcinoma, which showed raised concentrations in 23 out of 104 patients examined Of the 104 patients with pancreatic adenocarcinomas, positive serum CA19-9 concentrations (>37 U/ml) were found in 75 (72 1/%) cases, and positive serum CEA concentrations (>2-5 ng/ml) were noted in 53 (50 9%) cases (Table IV) . The serum concentrations of p53 protein did not correlate significantly with either CA19-9 or CEA concentrations (Table  IV) . Instead, positive serum p53 protein concentrations were found more often in patients negative for CA19-9 than patients positive for CA19-9 (Table IV) . Ofthe 22 patients showing both negative CA19-9 and CEA serum concentrations, six patients had positive concentrations of serum p53 protein (data not shown).
p53 PROTEIN IMMUNOHISTOCHEMISTRY Most of the p53 protein immunoreactivity was seen in the nuclei of carcinoma cells, and was found homogeneously in the carcinoma tissues (Fig 2) . An increasing relative ratio of p53 positive cells was found in sections that tended to show strong immunoreactivity. Negative=serum p53 protein <0 37 ng/ml; positive=serum p53 protein >0 37 ng/ml. Positive serum p53 concentrations were found in eight out of 28 (28-6%) positive immunostaining cases, but in only two out of 33 (6-1%) negative immunostaining cases (X2 test, p<005).
and chronic pancreatitis cases (data not shown).
Discussion
In the present study, we examined the serum concentrations of p53 antigen in cases of pancreatic cancer by ELISA, and analysed whether they correlated with the immunohistochemical staining for p53 protein.
To the best of our knowledge, there have been no previous reports on measuring the concentrations of serum p53 antigen in patients with pancreatic cancer. Serum p53 antigen concentrations in the cases of adenocarcinoma were significantly higher than in healthy blood donors or in patients with chronic pancreatitis. Moreover, patients with positive serum p53 antigen concentrations above 0 37 ng/ml were most often found in the adenocarcinoma group (22-1%). These results were similar to those from a recent report investigating serum p53 antigen concentrations by ELISA in colon carcinomas, in which raised concentrations were detected in 20% of the adenoma cases and in 32% of the carcinoma cases.5
In the present study, pancreatic adenocarcinomas with distant metastases showed significantly higher serum p53 concentrations than tumours without metastases. In addition, positive serum p53 concentrations were also found more often in patients with distant metastases (34 0%) than in those without metastases (12.3%). This is compatible with a previous study reporting that p53 gene mutations in pancreatic cancer cases may occur more often in metastatic lesions than in primary tumours.3 Fontanini et a16 also showed that the concentrations of mutant p53 antigen detected in the serum of patients with lung cancer were significantly higher in those patients with lymph node involvement and late stage disease. Furthermore, they also reported that the serum p53 antigen concentrations were associated with the extent of tumour Positive immunostaining by the anti-p53 protein DO-7 antibody was found in 45 9% of cases of pancreatic adenocarcinoma, which is similar to the results from previous reports'6 28 29 which showed p53 gene overexpression in 62 out of 133 (47%/o), in 16 out of 34 (47%), and in 19 out of 48 (40%) cases of adenocarcinoma, using DO-7, the PAb 1801 monoclonal antibody, and the CM-1 polyclonal antibody respectively. However, our incidence of positive immunoreactivity was slightly lower than in the other reports.8 30 This is probably due to differences in the antibody used, the preparation of the sections, and the method of evaluation.
There was more frequent positive p53 antigen immunostaining in the metastatic cases (55-6%) than in the primary cases (41-9%), although this difference was not significant. This is compatible with the serum p53 protein results, which showed higher p53 concentrations in patients with distant metastases than in those without. We used two different antibodies: PAb 240 for the ELISA and DO-7 for the immunohistochemistry. PAb 240 only recognises the mutant form of the p53 protein,"9 whereas DO-7 recognises both wild type and mutant forms.20 However, the wild type p53 protien is usually undetectable by DO-7 because of its short half life. Therefore, it is probable that the results obtained by both antibodies are compatible.
For the correlation between serum p53 antigen concentrations and p53 protein immunostaining, a high specificity (80%) was shown for the serum p53 protein concentrations, but the sensitivity was not as high.
Twenty of the 28 (71 4%) positive immunostaining cases were negative for the serum p53 antigen by ELISA, and were considered to be false negatives. On the other hand, two of the 33 (6 1%) negative immunostaining cases were positive on the ELISA, and were considered to be false positives. The reason for these falsenegative cases may be the fact that not all tumours with p53 gene overexpression necessarily release p53 protein into the blood stream,5 or that the presence of p53 protein antibodies can impair the detection of p53 protein in the serum. 7 The false positives could have resulted from an underestimation of the p53 protein immunostaining due to the heterogeneity of the tumour cells. Alternatively, they could have arisen from non-specific cross reactions with other serum proteins that have similar epitopes to p53,5 or from a stabilisation of the p53 protein due to binding with other serum proteins via an unknown mechanism. However, there may have been more positive p53 immunostaining cases in the patients with serum positive p53 concentrations in this study than were actually detected, because 13 out of the 23 patients with serum positive p53 concentrations were unresectable cases, and thus their tumour specimens were not available for immunohistochemistry. Therefore, the serum concentrations of p53 protein are expected to be more closely correlated with p53 antigen immunostaining in tumour cells than was actually reported here.
As p53 is the most frequent gene to be mutated in human cancers, it is a popular target for therapy. Recently, antisense oligonucleotides targeting the p53 gene have been reported to have an antiproliferative effect in various cell lines such as acute myeloid leukaemia, chronic myeloid leukaemia, and pancreatic cancers by the suppression of p53 gene expression.31-33 Moreover, Fan et al showed that the p53 gene status was an important determinant of both radiosensitivity and chemosensitivity in lymphoid cell lines, and that p53 mutations were often associated with a decreased sensitivity to DNA damaging agents.34 Therefore, the investigation of p53 gene alterations in pancreatic cancers is important for the selection of therapeutic treatments, especially in cases of unresectable tumours.
In conclusion, an increase in serum p53 antigen concentrations can represent an accumulation of the p53 protein, which results from mutations of the p53 gene. It would seem that the serum p53 protein concentrations represent different biological processes from tumour markers such as CA19-9 or CEA. In the future, assaying serum p53 protein concentrations may be a procedure for the detection of p53 gene alterations, by which we could select the best therapeutic regimens in patients with pancreatic carcinomas.
patients with pancreatic carcinomas. 
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